Clinical Significance of Heparin-binding Epidermal Growth Factor-like Growth Factor in Peritoneal Fluid of Ovarian Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2005 Apr 14

PMID 15827558

Citations 22

Authors

H Yagi

S Miyamoto

Y Tanaka

K Sonoda

H Kobayashi

T Kishikawa

R Iwamoto

E Mekada

H Nakano

Affiliations

Soon will be listed here.

Abstract

Epidermal growth factor receptor (EGFR) has been implicated in tumour growth and extension of ovarian cancer. Peritoneal fluid in ovarian cancer patients contains various growth factors that can promote tumour growth and extension. In order to investigate the clinical significance of EGFR ligands as activating factors of ovarian cancer, we examined the cell proliferation-promoting activity and the level of EGFR ligands in peritoneal fluid obtained from 99 patients. Proliferation-promoting activity in peritoneal fluid from 63 ovarian cancer patients (OVCA) was much higher than peritoneal fluid from 18 ovarian cyst patients (OVC) and 18 normal ovary patients (NO), and the activity was suppressed only by antibodies against EGFR or heparin-binding epidermal growth factor (HB-EGF). A large difference was observed in the level of EGFR ligands between HB-EGF and TGF-alpha or amphiregulin. The concentration of HB-EGF in OVCA significantly increased compared to that in OVC or NO (P<0.01). No significant difference in the concentration of TGF-alpha and amphiregulin was found between the OVCA and NO or OVC groups. In peritoneal fluid, HB-EGF is sufficiently elevated to activate cancer cells even at an early stage of OVCA. These results suggested that HB-EGF in peritoneal fluid might play a key role in cell survival and in the proliferation of OVCA.

Citing Articles

Amphiregulin Downregulates E-cadherin Expression by Activating YAP/Egr-1/Slug Signaling in SKOV3 Human Ovarian Cancer Cells.

Jia Q, Wang H, Bi B, Han X, Jia Y, Zhang L Reprod Sci. 2024; 32(2):404-416.

PMID: 39138796 DOI: 10.1007/s43032-024-01673-x.

The Multiple Functions of HB-EGF in Female Reproduction and Related Cancer: Molecular Mechanisms and Targeting Strategies.

Zhang Y, Tang L, Liu H, Cheng Y Reprod Sci. 2024; 31(9):2588-2603.

PMID: 38424408 DOI: 10.1007/s43032-024-01454-6.

Cell-free ascites from ovarian cancer patients induces Warburg metabolism and cell proliferation through TGFβ-ERK signaling.

Szeocs D, Vida B, Petovari G, Poliska S, Janka E, Sipos A Geroscience. 2024; 46(4):3581-3597.

PMID: 38196068 PMC: 11226691. DOI: 10.1007/s11357-023-01056-1.

The role of amphiregulin in ovarian function and disease.

Fang L, Sun Y, Cheng J Cell Mol Life Sci. 2023; 80(3):60.

PMID: 36749397 PMC: 11071807. DOI: 10.1007/s00018-023-04709-8.

HB-EGF induces mitochondrial dysfunction via estrogen hypersecretion in granulosa cells dependent on cAMP-PKA-JNK/ERK-Ca-FOXO1 pathway.

Huang J, Duan C, Jin S, Sheng C, Wang Y, Yue Z Int J Biol Sci. 2022; 18(5):2047-2059.

PMID: 35342363 PMC: 8935223. DOI: 10.7150/ijbs.69343.

References

Penson R, Shannon K, Sharpless N, Seiden M . Ovarian cancer: an update on genetics and therapy. Compr Ther. 1998; 24(10):477-87. View

Yeo E, EXTON J . Stimulation of phospholipase D by epidermal growth factor requires protein kinase C activation in Swiss 3T3 cells. J Biol Chem. 1995; 270(8):3980-8. DOI: 10.1074/jbc.270.8.3980. View

Goetzl E, Kong Y, KENNEY J . Lysophospholipid enhancement of human T cell sensitivity to diphtheria toxin by increased expression of heparin-binding epidermal growth factor. Proc Assoc Am Physicians. 1999; 111(3):259-69. DOI: 10.1046/j.1525-1381.1999.99116.x. View

Salomon D, Brandt R, Ciardiello F, Normanno N . Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995; 19(3):183-232. DOI: 10.1016/1040-8428(94)00144-i. View

Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C . EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature. 2000; 402(6764):884-8. DOI: 10.1038/47260. View

Westermann A, Beijnen J, Moolenaar W, Rodenhuis S . Growth factors in human ovarian cancer. Cancer Treat Rev. 1997; 23(2):113-31. DOI: 10.1016/s0305-7372(97)90024-4. View

Raab G, Klagsbrun M . Heparin-binding EGF-like growth factor. Biochim Biophys Acta. 1998; 1333(3):F179-99. DOI: 10.1016/s0304-419x(97)00024-3. View

Westermann A, Havik E, Postma F, Beijnen J, Dalesio O, Moolenaar W . Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann Oncol. 1998; 9(4):437-42. DOI: 10.1023/a:1008217129273. View

Jayne D, Perry S, Morrison E, Farmery S, Guillou P . Activated mesothelial cells produce heparin-binding growth factors: implications for tumour metastases. Br J Cancer. 2000; 82(6):1233-8. PMC: 2363354. DOI: 10.1054/bjoc.1999.1068. View

10.

Eder A, Sasagawa T, Mao M, Aoki J, Mills G . Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. Clin Cancer Res. 2000; 6(6):2482-91. View

11.

Iwamoto R, Mekada E . Heparin-binding EGF-like growth factor: a juxtacrine growth factor. Cytokine Growth Factor Rev. 2000; 11(4):335-44. DOI: 10.1016/s1359-6101(00)00013-7. View

12.

Xiao Y, Schwartz B, Washington M, Kennedy A, Webster K, Belinson J . Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. Anal Biochem. 2001; 290(2):302-13. DOI: 10.1006/abio.2001.5000. View

13.

Strachan L, Murison J, Prestidge R, Sleeman M, Watson J, Kumble K . Cloning and biological activity of epigen, a novel member of the epidermal growth factor superfamily. J Biol Chem. 2001; 276(21):18265-71. DOI: 10.1074/jbc.M006935200. View

14.

Umata T, Hirata M, Takahashi T, Ryu F, Shida S, Takahashi Y . A dual signaling cascade that regulates the ectodomain shedding of heparin-binding epidermal growth factor-like growth factor. J Biol Chem. 2001; 276(32):30475-82. DOI: 10.1074/jbc.M103673200. View

15.

DAntonio A, Losito S, Pignata S, Grassi M, Perrone F, De Luca A . Transforming growth factor alpha, amphiregulin and cripto-1 are frequently expressed in advanced human ovarian carcinomas. Int J Oncol. 2002; 21(5):941-8. View

16.

Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback D . Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol. 2002; 20(21):4292-302. DOI: 10.1200/JCO.2002.03.100. View

17.

Normanno N, Bianco C, De Luca A, Maiello M, Salomon D . Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer. 2003; 10(1):1-21. DOI: 10.1677/erc.0.0100001. View

18.

Gschwind A, Hart S, Fischer O, Ullrich A . TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. EMBO J. 2003; 22(10):2411-21. PMC: 155989. DOI: 10.1093/emboj/cdg231. View

19.

Mills G, Moolenaar W . The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer. 2003; 3(8):582-91. DOI: 10.1038/nrc1143. View

20.

Fischer O, Hart S, Gschwind A, Ullrich A . EGFR signal transactivation in cancer cells. Biochem Soc Trans. 2003; 31(Pt 6):1203-8. DOI: 10.1042/bst0311203. View